CN103370051A - 用于口服给药的选择性因子Xa抑制剂的药物组成物 - Google Patents

用于口服给药的选择性因子Xa抑制剂的药物组成物 Download PDF

Info

Publication number
CN103370051A
CN103370051A CN2011800604167A CN201180060416A CN103370051A CN 103370051 A CN103370051 A CN 103370051A CN 2011800604167 A CN2011800604167 A CN 2011800604167A CN 201180060416 A CN201180060416 A CN 201180060416A CN 103370051 A CN103370051 A CN 103370051A
Authority
CN
China
Prior art keywords
pharmaceutical composition
inhibitor
dosage form
selective factor
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800604167A
Other languages
English (en)
Chinese (zh)
Inventor
托马斯·W·伦纳德
戴维·C·库格林
艾伦·卡伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrion Research Ill Ltd
Original Assignee
Merrion Research Ill Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrion Research Ill Ltd filed Critical Merrion Research Ill Ltd
Publication of CN103370051A publication Critical patent/CN103370051A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800604167A 2010-12-15 2011-09-23 用于口服给药的选择性因子Xa抑制剂的药物组成物 Pending CN103370051A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42326110P 2010-12-15 2010-12-15
US61/423,261 2010-12-15
PCT/US2011/052963 WO2012082209A1 (en) 2010-12-15 2011-09-23 Pharmaceutical compositions of selective factor xa inhibitors for oral administration

Publications (1)

Publication Number Publication Date
CN103370051A true CN103370051A (zh) 2013-10-23

Family

ID=46234738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800604167A Pending CN103370051A (zh) 2010-12-15 2011-09-23 用于口服给药的选择性因子Xa抑制剂的药物组成物

Country Status (10)

Country Link
US (1) US20120156294A1 (https=)
EP (1) EP2651395A4 (https=)
JP (1) JP2013545802A (https=)
KR (1) KR20140046395A (https=)
CN (1) CN103370051A (https=)
AU (1) AU2011341637A1 (https=)
BR (1) BR112013014940A2 (https=)
CA (1) CA2819108A1 (https=)
MX (1) MX2013006877A (https=)
WO (1) WO2012082209A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108148102A (zh) * 2016-12-03 2018-06-12 烟台东诚药业集团股份有限公司 喷雾干燥法制备低水分磺达肝癸钠原料药

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
US12213972B2 (en) * 2022-07-27 2025-02-04 Slayback Pharma Llc Stable pharmaceutical compositions of apixaban

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050012A1 (en) * 1999-02-22 2000-08-31 Elan Corporation, Plc Solid oral dosage form containing an enhancer
WO2010032140A2 (en) * 2008-09-17 2010-03-25 Chiasma Inc. Pharmaceutical compositions and related methods of delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064148A2 (en) * 2001-02-16 2002-08-22 Shimizu Pharmaceutical Co., Ltd. Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
KR101191322B1 (ko) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 증진제를 함유하는 고형 경구용 투여 제형
CN107096012A (zh) * 2008-05-07 2017-08-29 诺和诺德股份有限公司 肽的组合物及其制备方法
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050012A1 (en) * 1999-02-22 2000-08-31 Elan Corporation, Plc Solid oral dosage form containing an enhancer
WO2010032140A2 (en) * 2008-09-17 2010-03-25 Chiasma Inc. Pharmaceutical compositions and related methods of delivery

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. CULLEN, T.W. LEONARD, ET AL.: ""Oral Delivery of Fondaparinux: A Potential Patient Benefit in Thrombosis Therapy"", 《POSTER PRESENTATION AT THE 2010 AAPS ANNUAL MEETING AND EXPOSITION》 *
A.VETTER, ET AL.: ""Development and in vivo bioavailability study of an oral fondaparinux delivery system"", 《EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES》 *
LEONARD TW, ET AL.: ""Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET"", 《EXPERT OPIN DRUG DELIV》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108148102A (zh) * 2016-12-03 2018-06-12 烟台东诚药业集团股份有限公司 喷雾干燥法制备低水分磺达肝癸钠原料药

Also Published As

Publication number Publication date
AU2011341637A1 (en) 2013-06-20
MX2013006877A (es) 2013-07-05
CA2819108A1 (en) 2012-06-21
JP2013545802A (ja) 2013-12-26
EP2651395A1 (en) 2013-10-23
KR20140046395A (ko) 2014-04-18
BR112013014940A2 (pt) 2016-09-13
WO2012082209A1 (en) 2012-06-21
EP2651395A4 (en) 2014-05-07
US20120156294A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
US20240082231A1 (en) Niraparib formulations
US9089484B2 (en) Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CN103370051A (zh) 用于口服给药的选择性因子Xa抑制剂的药物组成物
JP4879351B2 (ja) 医薬固形製剤
KR20100126452A (ko) 난용성 약물용 약학적 조성물
US20100086592A1 (en) Modified dosage forms of tacrolimus
KR101858797B1 (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
CN101466384A (zh) 包含促释剂的渗透递药系统
US11077114B2 (en) Stabilized formulations of CNS compounds
WO2013175494A2 (en) Controlled release pharmaceutical formulations of direct thrombin inhibitors
US10493067B2 (en) Method of treating heart failure with preserved ejection fraction by administering milrinone
US8741345B2 (en) Modified release pharmaceutical compositions of dexlansoprazole
US9180198B2 (en) Slow-release cilostazol tablet having an improved elution rate and minimal side effects
JP6904955B2 (ja) アプレミラスト徐放性製剤
US20050118256A1 (en) Extended release alpha-2 agonist pharmaceutical dosage forms
WO2021074808A1 (en) Pharmaceutical composition comprising sacubitril and valsartan and process for preparation thereof
AU2007258325B2 (en) Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders
US20130165459A1 (en) Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
TW202313072A (zh) 檸檬酸鐵之兒科調配物
US12527803B2 (en) Testosterone dodecanoate compositions and methods
JP6359234B2 (ja) 動物用徐放性製剤組成物
WO2013168179A2 (en) Controlled release pharmaceutical formulations of antiviral agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131023